<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_dasatinib" title="Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets" shortTitle="dasatinib" author="Ildikó Beke Debreceni, Gabriella Mezei, Péter Batár, Árpád Illés, János Kappelmayer" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1422-0067/20/21/5430/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Tyrosine	NN	tyrosine
kinase	NN	kinase
inhibitors	NNS	inhibitor
(	-LRB-	(
TKIs	NNS	Tkis
)	-RRB-	)
are	VBP	be
widely	RB	widely
used	VBN	use
drugs	NNS	drug
as	IN	as
a	DT	a
targeted	VBN	target
strategy	NN	strategy
for	IN	for
cancer	NN	cancer
treatment	NN	treatment
with	IN	with
the	DT	the
aim	NN	aim
of	IN	of
prolonging	VBG	prolong
progression-free	JJ	progression-free
survival	NN	survival
.	.	.
</s>
<s type="decl">
Deregulated	VBN	Deregulate
tyrosine	NN	tyrosine
kinase	NN	kinase
activity	NN	activity
of	IN	of
the	DT	the
BCR-ABL	NNP	BCR-ABL
oncoprotein	NN	oncoprotein
is	VBZ	be
the	DT	the
biochemical	JJ	biochemical
hallmark	NN	hallmark
of	IN	of
Philadelphia	NNP	Philadelphia
chromosome-positive	NN	chromosome-positive
(	-LRB-	(
Ph+	NNP	Ph+
)	-RRB-	)
hematological	JJ	hematological
malignancies	NNS	malignancy
.	.	.
</s>
<s type="decl">
Currently	RB	currently
,	,	,
several	JJ	several
generations	NNS	generation
of	IN	of
BCR-ABL	NNP	BCR-ABL
TKIs	NNS	Tkis
are	VBP	be
in	IN	in
clinical	JJ	clinical
use	NN	use
for	IN	for
treatment	NN	treatment
of	IN	of
these	DT	this
malignancies	NNS	malignancy
.	.	.
</s>
<s type="decl">
Introduction	NN	introduction
of	IN	of
the	DT	the
second-generation	NN	second-generation
TKIs	NNP	Tkis
,	,	,
nilotinib	NN	nilotinib
and	CC	and
dasatinib	NN	dasatinib
as	IN	as
first-line	JJ	first-line
treatment	NN	treatment
resulted	VBD	result
in	IN	in
rapid	JJ	rapid
and	CC	and
deep	JJ	deep
reduction	NN	reduction
of	IN	of
BCR/ABL1	NNP	BCR/ABL1
allele	NN	allele
transcripts	NNS	transcript
,	,	,
and	CC	and
this	DT	this
provided	VBD	provide
a	DT	a
possibility	NN	possibility
for	IN	for
long-term	JJ	long-term
survival	NN	survival
in	IN	in
CML	NNP	CML
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
to	IN	to
CML	NNP	CML
,	,	,
several	JJ	several
other	JJ	other
patient	NN	patient
populations	NNS	population
were	VBD	be
identified	VBN	identify
that	WDT	that
undoubtedly	RB	undoubtedly
benefited	VBD	benefit
from	IN	from
TKI	NNP	TKI
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
Patients	NNS	patient
with	IN	with
Ph+	NNP	Ph+
adult	NN	adult
acute	JJ	acute
lymphoblastic	JJ	lymphoblastic
leukemia	NN	leukemia
(	-LRB-	(
ALL	NNP	ALL
)	-RRB-	)
may	MD	may
also	RB	also
benefit	VB	benefit
from	IN	from
an	DT	a
alternate	JJ	alternate
TKI	NNP	TKI
therapy	NN	therapy
.	.	.
</s>
<s type="frag">
In	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
pediatric	JJ	pediatric
patients	NNS	patient
with	IN	with
Ph+	NNP	Ph+
ALL	NN	ALL
</s>
<s type="decl">
the	DT	the
addition	NN	addition
of	IN	of
TKIs	NN	Tkis
to	IN	to
conventional	JJ	conventional
chemotherapy	NN	chemotherapy
has	VBZ	have
improved	VBN	improve
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
.	.	.
</s>
<s type="decl">
It	PRP	it
has	VBZ	have
long	RB	long
been	VBN	be
known	VBN	know
that	IN	that
second-generation	NN	second-generation
TKIs	NNS	Tkis
may	MD	may
have	VB	have
side	NN	side
effects	NNS	effect
as	IN	as
nilotinib	NN	nilotinib
can	MD	can
potentiate	VB	potentiate
a	DT	a
prothrombotic	JJ	prothrombotic
state	NN	state
while	IN	while
dasatinib	NN	dasatinib
is	VBZ	be
known	VBN	know
to	TO	to
cause	VB	cause
platelet	NN	platelet
dysfunction	NN	dysfunction
e.g.	RB	e.g.
impaired	JJ	impaired
collagen-induced	JJ	collagen-induced
platelet	NN	platelet
adhesion	NN	adhesion
and	CC	and
aggregation	NN	aggregation
.	.	.
</s>
<s type="decl">
Although	IN	although
both	DT	both
drugs	NNS	drug
bind	VBP	bind
to	IN	to
the	DT	the
ATP	NNP	ATP
binding	VBG	bind
site	NN	site
of	IN	of
the	DT	the
kinase	NN	kinase
domain	NN	domain
of	IN	of
the	DT	the
BCR/ABL	NNP	BCR/ABL
protein	NN	protein
</s>
<s type="decl">
they	PRP	they
have	VBP	have
different	JJ	different
off	JJ	off
target	NN	target
inhibitory	JJ	inhibitory
effect	NN	effect
on	IN	on
several	JJ	several
other	JJ	other
tyrosine	NN	tyrosine
kinases	NNS	kinase
.	.	.
</s>
<s type="decl">
Dasatinib	NNP	Dasatinib
is	VBZ	be
a	DT	a
potent	JJ	potent
multikinase	NN	multikinase
inhibitor	NN	inhibitor
,	,	,
including	VBG	include
c-KIT	NN	c-KIT
,	,	,
EPHA2	NNP	EPHA2
,	,	,
platelet-derived	NN	platelet-derived
growth	NN	growth
factor	NN	factor
receptor-β	NN	receptor-β
,	,	,
and	CC	and
SFKs	NNP	SFK
.	.	.
</s>
<s type="decl">
Nilotinib	NNP	Nilotinib
is	VBZ	be
also	RB	also
a	DT	a
second	JJ	second
generation	NN	generation
TKI	NNP	TKI
with	IN	with
a	DT	a
broad	JJ	broad
inhibitory	NN	inhibitory
spectrum	NN	spectrum
of	IN	of
various	JJ	various
tyrosine	NN	tyrosine
kinases	NNS	kinase
(	-LRB-	(
PDGFR	NNP	PDGFR
,	,	,
c-KIT	NNP	c-KIT
,	,	,
ARG	NNP	ARG
,	,	,
EPHB4	NNP	EphB4
)	-RRB-	)
,	,	,
but	CC	but
it	PRP	it
does	VBZ	do
not	RB	not
inhibit	VB	inhibit
SFKs	NNS	SFK
.	.	.
</s>
<s type="decl">
Previous	JJ	previous
in	IN	in
vitro	NN	vitro
and	CC	and
ex	NN	ex
vivo	NN	vivo
studies	NNS	study
with	IN	with
dasatinib	NN	dasatinib
have	VBP	have
demonstrated	VBN	demonstrate
a	DT	a
faulty	JJ	faulty
platelet	NN	platelet
aggregation	NN	aggregation
.	.	.
</s>
<s type="decl">
On	IN	on
the	DT	the
contrary	JJ	contrary
nilotinib	NN	nilotinib
has	VBZ	have
no	DT	no
effect	NN	effect
on	IN	on
platelet	NN	platelet
aggregation	NN	aggregation
,	,	,
at	IN	at
all	DT	all
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
we	PRP	we
used	VBD	use
nilotinib	NN	nilotinib
as	IN	as
a	DT	a
negative	JJ	negative
control	NN	control
in	IN	in
our	PRP$	our
experiments	NNS	experiment
.	.	.
</s>
</p>
<p>
<s type="decl">
Sarcoma	NNP	Sarcoma
family	NN	family
kinases	NNS	kinase
(	-LRB-	(
SFKs	NNS	SFK
)	-RRB-	)
are	VBP	be
critical	JJ	critical
regulators	NNS	regulator
of	IN	of
platelet	NN	platelet
signaling	NN	signaling
and	CC	and
activation	NN	activation
.	.	.
</s>
<s type="decl">
These	DT	this
kinases	NNS	kinase
play	VBP	play
a	DT	a
central	JJ	central
role	NN	role
in	IN	in
mediating	VBG	mediate
rapid	JJ	rapid
response	NN	response
of	IN	of
platelets	NNS	platelet
to	IN	to
vascular	JJ	vascular
injury	NN	injury
.	.	.
</s>
<s type="decl">
They	PRP	they
transmit	VBP	transmit
activation	NN	activation
signals	NNS	signal
from	IN	from
several	JJ	several
various	JJ	various
platelet	NN	platelet
receptors	NNS	receptor
.	.	.
</s>
<s type="decl">
There	EX	there
are	VBP	be
numerous	JJ	numerous
members	NNS	member
of	IN	of
this	DT	this
group	NN	group
and	CC	and
among	IN	among
the	DT	the
SFKs	NNPS	SFK
Lyn	NNP	Lyn
,	,	,
Fyn	NNP	Fyn
,	,	,
and	CC	and
Src	NNP	Src
have	VBP	have
been	VBN	be
implicated	VBN	implicate
in	IN	in
activation	NN	activation
of	IN	of
the	DT	the
GPVI	NNP	GPVI
receptor	NN	receptor
and	CC	and
the	DT	the
integrin	NN	integrin
receptor	NN	receptor
signaling	NN	signaling
and	CC	and
are	VBP	be
frequently	RB	frequently
studied	VBN	study
proteins	NNS	protein
as	IN	as
they	PRP	they
are	VBP	be
present	JJ	present
in	IN	in
both	CC	both
human	JJ	human
and	CC	and
mouse	NN	mouse
platelets	NNS	platelet
.	.	.
</s>
<s type="decl">
TKIs	NNPS	Tkis
have	VBP	have
a	DT	a
different	JJ	different
off-target	JJ	off-target
multikinase	NN	multikinase
inhibitory	NN	inhibitory
effect	NN	effect
.	.	.
</s>
<s type="decl">
Comprehensive	JJ	Comprehensive
drug-protein	JJ	drug-protein
interaction	NN	interaction
profiles	NNS	profile
were	VBD	be
described	VBN	describe
to	TO	to
predict	VB	predict
the	DT	the
potential	JJ	potential
side	NN	side
effects	NNS	effect
of	IN	of
BCR-ABL	NNP	BCR-ABL
TKIs	NNP	Tkis
.	.	.
</s>
<s type="decl">
It	PRP	it
was	VBD	be
found	VBN	find
that	IN	that
the	DT	the
most	RBS	most
prominent	JJ	prominent
dasatinib-targeted	NNP	dasatinib-targeted
SFKs	NNS	SFK
are	VBP	be
Lyn	NNP	Lyn
,	,	,
Fyn	NNP	Fyn
,	,	,
and	CC	and
Src	NNP	Src
,	,	,
kinases	NNS	kinase
and	CC	and
their	PRP$	their
negative	JJ	negative
regulator	NN	regulator
C-terminal	NNP	C-terminal
Src	NNP	Src
kinase	NN	kinase
(	-LRB-	(
Csk	NNP	Csk
)	-RRB-	)
,	,	,
but	CC	but
nilotinib	NN	nilotinib
does	VBZ	do
not	RB	not
bind	VB	bind
to	IN	to
these	DT	this
kinases	NNS	kinase
.	.	.
</s>
<s type="decl">
During	IN	during
vascular	JJ	vascular
injury	NN	injury
it	PRP	it
is	VBZ	be
primarily	RB	primarily
the	DT	the
subendothelial	JJ	subendothelial
collagen	NN	collagen
that	WDT	that
activates	VBZ	activate
platelets	NNS	platelet
and	CC	and
result	VBP	result
in	IN	in
subsequent	JJ	subsequent
platelet	NN	platelet
aggregation	NN	aggregation
.	.	.
</s>
<s type="decl">
A	DT	a
population	NN	population
of	IN	of
the	DT	the
collagen-adhered	JJ	collagen-adhered
platelets	NNS	platelet
responds	VBZ	respond
by	IN	by
surface	NN	surface
exposure	NN	exposure
of	IN	of
the	DT	the
procoagulant	JJ	procoagulant
phosphatidylserine	NN	phosphatidylserine
(	-LRB-	(
PS	NNP	PS
)	-RRB-	)
.	.	.
</s>
<s type="decl">
This	DT	this
surface	NN	surface
expressed	VBD	express
PS	NNP	PS
facilitates	VBZ	facilitate
the	DT	the
binding	NN	binding
of	IN	of
coagulation	NN	coagulation
factors	NNS	factor
and	CC	and
by	IN	by
this	DT	this
promotes	VBZ	promote
thrombin	NN	thrombin
generation	NN	generation
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
platelets	NNS	platelet
participate	VBP	participate
in	IN	in
fibrin	NN	fibrin
formation	NN	formation
and	CC	and
regulate	VBP	regulate
the	DT	the
process	NN	process
of	IN	of
clot	NN	clot
retraction	NN	retraction
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
intended	VBD	intend
to	TO	to
investigate	VB	investigate
whether	IN	whether
dasatinib	NN	dasatinib
also	RB	also
affects	VBZ	affect
the	DT	the
platelet	NN	platelet
procoagulant	NN	procoagulant
activity	NN	activity
and	CC	and
thereby	RB	thereby
coagulation	NN	coagulation
.	.	.
</s>
<s type="decl">
For	IN	for
this	DT	this
reason	NN	reason
,	,	,
we	PRP	we
examined	VBD	examine
the	DT	the
in	NN	in
vitro	NN	vitro
and	CC	and
ex	NN	ex
vivo	NN	vivo
effects	NNS	effect
of	IN	of
dasatinib	NN	dasatinib
on	IN	on
platelet	NN	platelet
procoagulant	NN	procoagulant
response	NN	response
in	IN	in
dasatinib	NN	dasatinib
treated	VBN	treat
platelets	NNS	platelet
of	IN	of
healthy	JJ	healthy
volunteers	NNS	volunteer
and	CC	and
in	IN	in
samples	NNS	sample
derived	VBN	derive
from	IN	from
CML	NNP	CML
patients	NNS	patient
on	IN	on
dasatinib	NN	dasatinib
therapy	NN	therapy
.	.	.
</s>
<s type="decl">
We	PRP	we
found	VBD	find
that	IN	that
at	IN	at
therapeutic	JJ	therapeutic
concentration	NN	concentration
dasatainib	NN	dasatainib
,	,	,
but	CC	but
not	RB	not
nilotinib	JJ	nilotinib
,	,	,
has	VBZ	have
a	DT	a
strong	JJ	strong
inhibitory	JJ	inhibitory
effect	NN	effect
on	IN	on
platelet	NN	platelet
procoagulant	NN	procoagulant
activity	NN	activity
and	CC	and
on	IN	on
clot	NN	clot
retraction	NN	retraction
both	CC	both
in	IN	in
non	NN	non
activated	VBN	activate
as	RB	as
well	RB	well
as	IN	as
in	IN	in
convulxin	NN	convulxin
activated	VBN	activate
platelets	NNS	platelet
.	.	.
</s>
</p>
</text>